drugset / Trial / NCT00692939

Autologous Stem Cell Transplantation for Crohn's Disease

NCT00692939 ↗

Phase 1/2 Recruiting 20 enrolled Paul Szabolcs
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.

Timeline

Start
2012-06-26
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous CD34-selected peripheral blood stem cells transplant Cell therapy — —
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule — —
Background ATG Unknown — —
Background Alemtuzumab Monoclonal antibody — —
Background Cyclophosphamide Other / unclassified — —
Background G-CSF Unknown — —
Background Melphalan Small molecule — —
Background Rituximab Monoclonal antibody — —
Background Thiotepa Other / unclassified — —

Indications